CUVL (Clinuvel) - profitable peptide biotech, $226m EV, Phase 3 readout in less than 100 days. Cashed up, no debt.

New Nasdaq listing that almost nobody over here has looked at yet. It only started trading on the Nasdaq Global Select Market on 20 July 2026, so it has basically zero US coverage despite being profitable for nine straight years, and despite Sean Parker (Napster, Facebook) and Michael Polansky (Parker Institute, Lady Gaga's partner) having backed it for over 15 years.

Short version: $226m enterprise value for a business that did $26m of net profit last year at a 34% net margin, a Phase 3 readout in December on an indication the company sizes at $4.5b, and a peptide delivery platform sitting underneath it that isn't in the price at all.

# The numbers

Most biotech DD is a pre-revenue company burning cash into a binary. This isn't that. Clinuvel sells SCENESSE (afamelanotide), a melanocortin peptide implant, for EPP (erythropoietic protoporphyria), and has been profitable for nine consecutive years.

* Price $7.80, market cap \~$393m
* Cash $167m, zero debt, 21st consecutive year with no borrowings
* **EV \~$226m**
* Cash per share $3.31, so 42% of the share price is cash
* FY25: revenue $75.5m, pre-tax profit $37.0m, net profit $26.0m
* Net margin 34%, gross margin north of 90%
* Revenue CAGR 21% over 5 years, 35% over 9
* 8 consecutive dividends, entirely self funded, no raise, no dilution ever

That's roughly **9.7x EV/net profit** and about 17x earnings, for a >90% gross margin pharma compounding revenue at 20%+ with 42% of the market cap in cash.

Strip the cash out and you're paying about $4.49 a share for the operating business. Everything below is what you get on top of that.

# Vitiligo --> the major catalyst

CUV105 is the Phase 3 in vitiligo, running the same peptide that's already approved and generating revenue in EPP. Company's own US market model:

* 1% US prevalence = 3,295,000 people
* 25% eligible (Fitzpatrick IV-VI) = 823,750
* 40% meeting body-surface-area criteria = 329,500
* 20% actively seeking treatment = 65,900
* 9% penetration in years 1-2 = **5,931 patients**

Total addressable market: **$4.5b**. Years 1-2 revenue from those \~6,000 patients: **$490-570m**.

Against a $226m EV. Years 1-2 vitiligo revenue alone would be **2.2 to 2.5x the entire current enterprise value**, and roughly 7x total FY25 group revenue. From six thousand patients.

Also worth noting what it isn't. The competing approaches in vitiligo are immune suppression. This is a melanocortin peptide working through the pigmentation pathway itself, which is a different safety conversation for a chronic, lifelong condition. Their North American team has been pushing exactly that line at AAD for two years running.

Two things I think are underappreciated:

**1. The trial is fully recruited.** Over 200 patients enrolled, target hit. Recruitment risk is gone. This is a readout waiting to happen, not a trial still trying to fill sites.

**2. The commercial build is already done.** This is the bit that changes the shape of the ramp. 190 trained and accredited treatment centres, a 20 person national distribution team, NB-UVB systems, and the reimbursement pathway for extensive vitiligo have all been stood up in parallel with the trial. A positive readout doesn't kick off a two year commercial build. The channel already exists.

Worth remembering they already know how to sell an ultra-orphan peptide therapy through specialist centres with reimbursement. Same playbook they ran for EPP, into a market orders of magnitude larger.

# Why December is the inflection

Topline guided for December 2026. Roughly 100 days from now.

Right now the market prices this as an EPP company with a big cash pile. On a positive readout it reprices as a company with a multi hundred million dollar dermatology franchise ahead of it and the salesforce already hired.

Nearer term: FY26 full year results land in the next few days (27-28 August, with an investor webinar the same evening). Ninth consecutive profitable year, ninth dividend, and possibly a tightening of the December guidance to a specific window. A firmer date is usually what starts pulling attention in.

Then regulatory filings through 2027, into a market where the infrastructure is already standing.

# Scale

Not going to pretend to model this precisely, but on the midpoint of $530m of years 1-2 revenue across 50.4m shares, even at margins well below the 34% the company already runs at, you get earnings per share that are a multiple of the current price. The share count is the thing people underrate here. 50 million shares is tiny for a Nasdaq listing. Any material revenue lands very concentrated per share.

For reference, analyst targets on it sit in the $12 to $16.50 range against $7.80 today.

# The delivery platform, which is the part nobody is pricing

Vitiligo is the catalyst. This is the reason it could be a much bigger company in five years.

Peptides are the hottest category in US pharma right now. GLP-1s dragged the class into the mainstream and the policy environment has swung hard behind it: the FDA has been unwinding the 2023 restrictions on compounded peptides, and in July an FDA advisory panel voted to ease restrictions on most of the seven it reviewed. Grand View has the US peptide therapeutics market at roughly $65b in 2024 heading toward $160b by 2030, a 14.7% CAGR.

Clinuvel has been working on melanocortins since long before any of that was fashionable, and what they've quietly been building is the piece the whole category actually struggles with: **delivery.**

**VLRX-L** is their in-house controlled-release liquid injectable peptide platform, developed at VALLAURIX, their Singapore research centre. The point of it is flexible, reproducible controlled release. You adjust injection volume to titrate the dose, which means you can tailor to body weight and treat paediatric and adolescent patients rather than just adults. That's a genuinely hard problem in peptide delivery and it's often the difference between a drug that works and a drug patients stay on.

Where it's up to, per the 12 August update:

* Four candidate formulations went into a preclinical study to confirm the in vitro work
* One showed a superior release profile across the target delivery window, with lower peak plasma levels and drug still detectable across the period
* That candidate is now being refined, with a further preclinical study scheduled for early Q1 2027
* **Manufacturing scale-up is already being scoped**

That last point is the tell. You don't scope manufacturing scale-up on something you think is going nowhere.

The infrastructure behind it is real money. In December 2025 they announced an expansion of VALLAURIX backed by the Singapore Economic Development Board, up to S$30m over five years to 2030, roughly doubling the centre's footprint and adding specialist staff specifically to accelerate long-acting delivery platforms. R&D is now over 50 people under CSO Dr Dennis Wright. This is a decade-plus program in peptide chemistry, polymer science and delivery system design, funded out of operating cash flow while the company still posts a profit every half.

The strategic logic: initial focus is melanocortins, their own compounds. But the company has been explicit that VLRX-L and the other platforms under development at VALLAURIX could deliver **other peptides too**. If it validates in vivo, this stops being a formulation for one drug and becomes a platform, applicable to third party peptides, licensable, partnerable. In a category heading toward $160b where almost every player has a delivery problem, owning controlled-release technology is a different kind of asset to owning one drug.

They also have the credibility to make that claim, which most platform stories don't. SCENESSE is already a controlled-release peptide product, commercially approved and shipping across five jurisdictions for years. They aren't theorising about sustained-release peptide delivery. They've done it, at commercial scale, through multiple regulators.

None of this is in a $226m EV. The market is pricing one drug and some cash.

# The rest of the free pipeline

Also carrying zero value at the current price:

* NEURACTHEL (ACTH) for neurological and endocrinological indications
* PRENUMBRA for stroke, expanding toward Parkinson's
* DNA repair and polychromatic photoprotection in PhotoCosmetics
* EPP label expansion and new geographies (Health Canada approval came through recently)

Every one of those runs off the same melanocortin peptide science base and the same delivery work underneath it.

# My view

The existing EPP business plus $167m of cash covers most of the current share price on its own. Which means the December vitiligo readout is close to a free call option attached to a profitable, dividend paying, debt free company growing revenue 20% a year. And underneath that you get a peptide delivery platform, funded and progressing, in the hottest category in US pharma, for nothing.

You very rarely get a binary catalyst where the downside is backstopped by a real operating business and 42% of the market cap in cash. And because it only listed on Nasdaq a month ago, most US screens haven't even picked it up yet.